SCHEMBL650740

SCHEMBL650740

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1cccc(F)c1F)CC1CCCCC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.39
CCR4 P51679 4/20 0.38
OPRM1 P35372 4/20 0.36
OPRK1 P41145 4/20 0.36
TSHR P16473 4/20 0.36
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 3/20 0.36
CYP3A4 P08684 3/20 0.36
HSD17B10 Q99714 3/20 0.36
HPGD P15428 2/20 0.36
P2RX7 Q99572 1/20 0.36
HDAC1 Q13547 1/20 0.34
ADORA3 P0DMS8 2/20 0.34
ADORA2A P29274 2/20 0.34
ADORA2B P29275 2/20 0.34
ADORA1 P30542 2/20 0.34
BCHE P06276 1/20 0.34
ACHE P22303 1/20 0.34
ALOX15 P16050 1/20 0.34
CRHR1 P34998 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136106 0.94 C5AR1 (0.41) C5AR1CCR4OPRM1OPRK1TSHR
SCHEMBL651739 0.91 CCR4 (0.45) C5AR1CCR4OPRM1OPRK1TSHR
SCHEMBL5135466 0.91 C5AR1 (0.39) C5AR1CCR4TSHRKDM4EALDH1A1
SCHEMBL5136466 0.89 C5AR1 (0.42) C5AR1CCR4TSHRKDM4EALDH1A1
SCHEMBL5136891 0.88 C5AR1 (0.41) C5AR1CCR4TSHRKDM4EALDH1A1
SCHEMBL648934 0.88 CCR4 (0.40) C5AR1CCR4OPRM1OPRK1TSHR
SCHEMBL5135938 0.87 C5AR1 (0.41) C5AR1CCR4TSHRKDM4EALDH1A1
SCHEMBL651501 0.87 C5AR1 (0.44) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL5137300 0.87 CCR4 (0.49) C5AR1CCR4TSHRKDM4EALDH1A1
SCHEMBL5135152 0.87 C5AR1 (0.41) C5AR1CCR4TSHRKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed